Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ effects on cognitive function in patients with advanced prostate cancer (Abstract 5005).
Jana de Boniface, MD, PhD, of Capio Saint Göran's Hospital and Karolinska Institutet, reviews overall survival and patient-reported arm morbidity findings from the SENOMAC trial, which sought to determine if patients with breast cancer and sentinel lymph node macrometastases could omit complete axillary dissection (Abstract LBA503).
Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515).
Krishnan R. Patel, MD, of the National Cancer Institute, discusses a combined analysis of the NRG/RTOG 9202, 9413, 9902, and 0521 trials that looked at using clinico-transcriptomic risk stratification to guide abiraterone treatment intensification among patients with high-risk prostate cancer (Abstract 5000).
Veronica Diermayr, PhD, of EDDC and A*STAR, discusses the use of artificial intelligence (AI) driven strategy called H&E 2.0 in gastric and esophageal cancer. Researchers tested the feasibility of training deep-learning models on hematoxylin and eosin images of gastroesophageal carcinomas and their ability to predict EBC-129 antigen expression directly from these images. EBC-129 is an experimental antibody-drug conjugate that targets N256-glycosylated CEACAM5/6, which is highly expressed on solid tumors, including gastroesophageal cancers (Abstract 4018).
Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC) treatment. After decades of limited treatment progress, advances are being seen in immunotherapies, radiation therapy, bispecific T-cell engagers, antibody-drug conjugates, and radionuclide therapies.
